QingSong Health (SEHK:2661) Stock Price Mirrors Revenue Slide And Fresh Loss

The market is still treating QingSong Health like a busted growth story, with the stock down about 79% over the past 90 days. However, today’s earnings tell a more complicated tale. The headline is not the loss itself; it is the pressure on profitability, with H1 2026 revenue at ¥358.2m against a net loss of ¥51.4m and a basic loss per share of ¥0.25. For a healthcare stock that had already reported sizeable trailing losses, this latest squeeze on earnings is what matters for where the balance of risk and reward now sits.

Love the healthcare exposure with QingSong Health but concerned about the recent squeeze on earnings and profitability? Check out the list of solid balance sheet and fundamentals stocks (423 results) as a benchmark for companies where revenues are backed by stronger balance sheets and more resilient fundamentals.

H1 2026 Earnings Summary

• Revenue H1 2026 vs. H1 2025: ¥358.2m vs. ¥656.1m (revenue declined 45.4%)
• Net Loss H1 2026 vs. H1 2025: ¥51.4m loss vs. ¥86.0m profit (moved from profit to loss)
• Basic EPS H1 2026 vs. H1 2025: ¥0.25 loss per share vs. ¥1.07 earnings per share (earnings per share swung into loss)
• Trailing Twelve Month Net Loss vs. H1 2025 Net Income: ¥517.1m loss vs. ¥80.4m profit (losses widened significantly over the trailing period)

Prefer clean charts instead of another wall of earnings tables and raw figures? See QingSong Health's full visual breakdown, with a clear view of how its financials stack up across the latest results, in the company report for QingSong Health.

QingSong Health’s Growth Story Faces Near-Term Test

For investors leaning bullish on QingSong Health as a scalable digital health and insurance platform, the latest figures are a clear reality check. Revenue of ¥358.2m in H1 2026 compared with ¥656.1m a year earlier runs against a high growth platform narrative. The move from a ¥86.0m profit in H1 2025 to a ¥51.4m loss also makes it harder to argue that operating leverage is starting to work. Any positive long term story now rests on whether the current reset can stabilise volumes and rebuild earnings quality.

Bearish Concerns On Profitability Find Fresh Support

The more cautious view on QingSong Health finds support in these results. The shift from earnings per share of ¥1.07 in H1 2025 to a ¥0.25 loss per share, alongside a trailing twelve month net loss of ¥517.1m versus prior net income of ¥80.4m, points to meaningful earnings pressure. Revenue contraction and sustained losses sit uncomfortably with a complex business model that spans digital health content, services and insurance brokerage. With the share price down about 79% over 90 days, the market clearly treats execution and balance of risk as open questions.

After earnings that moved from profit to loss and a share price that has swung sharply, it is fair to ask whether the visible issues around QingSong Health are the full story or just early signs of deeper fragility. Review our independent risk analysis for QingSong Health which shows 2 important warning signs

Stay Ahead Of Your Next Move

If QingSong Health's swing from profit to loss has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for a setup that fits your plan. Once you commit capital, use the Portfolio Command Center to cut through noise and keep focus on the most important developments that could affect your holdings. For longer term conviction checks and fresh angles, lean on the Community to see how other investors are thinking about the same risks and opportunities. This way you surface potential catalysts and red flags earlier and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond QingSong Health?

Fresh ideas move fast. Some stocks are building quiet momentum, others are dropping back before a potential breakout. Scan these curated shortlists before the crowd while it matters and act now.

• Spot sturdier balance sheets and steadier earnings profiles by reviewing a hand picked list of solid balance sheet and fundamentals stocks (423 results) that can complement or contrast what you see in QingSong Health.
• Chase high potential growth stories that many investors have not caught yet by scanning 608 high quality undiscovered gems that remain under the radar for now but will not stay quiet forever.
• Target consistent income ideas while others focus only on headlines by checking a curated set of 409 dividend fortresses before yields and entry points move away from today’s levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com